Clostridium Difficile Infections - A Pipeline Analysis Report

Overview of the drug development pipeline for clostridium difficile infections

It is a Gram-positive and spore-forming bacterium, which causes inflammation in the colon called colitis. People with other diseases or conditions that require longer usage of antibiotics and the older people are at high risk of developing C. difficile infection. In July 2016, the European Centre for Disease Prevention and Control (ECDC) announced that the 2011-2012 ECDC point prevalence survey of healthcare associated infections and antimicrobial use in European acute care hospitals estimated that about 123,997 patients had C. difficile infections every year. In 2013, the US Department of Health and Human Services estimated that at least 14,000 people would die each year in the US due to the increasing infections caused by Clostridium Difficile infections. As a result, the rising instances of the disease are expected to proliferate the drug development for clostridium difficile infections during the next few years.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for clostridium difficile infections. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of clostridium difficile infections. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Astellas Pharma
• Evec
• Osel
• Otsuka Pharmaceuticals
• Pfizer

Therapeutic assessment of the drug development pipeline for clostridium difficile infections by route of administration

• Oral
• Intramuscular
• Subcutaneous
• Rectal
• Topical, parenteral, and aerosol

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for clostridium difficile infections by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for clostridium difficile infections are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for clostridium difficile infections?
• What are the companies that are currently involved in the development of drug molecules for clostridium difficile infections?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.